Facts

Cipla International

• Cipla Medpro was born from a joint venture between Cipla International and South African company Medpro Pharmaceutica.
• Cipla is one of the largest generic and chronic medicines manufacturers in Asia, with research, development and manufacturing facilities worldwide.
• Cipla International's advanced technology, stringent production and extensive research and development ensure that Cipla Medpro medicines are manufactured according to the highest international GMP standards.
• Cipla was established in 1935.
• Cipla exports to 170 countries, including the USA, UK, Australia and Germany.
• Cipla manufactures 40 billion tablets per year.
• Cipla's manufacturing facilities are approved by the World Health Organisation, (WHO), America's FDA, Britain's MHRA, South Africa's MCC, Germany's PIC and Australia's TGA, amongst many others.
• Cipla was responsible for initially lowering the cost of Triple ARV Therapy to less than $1 per day.
• Cipla is in partnership with the Clinton Foundation to supply ARVs to 3rd world countries.
• Cipla has the widest range of respiratory products.
• Cipla produces 150 million inhalers per year.
• Cipla was the only company that could supply the USA with enough Ciprofloxacin during the Anthrax scare.
• Cipla has established a Chest Research Foundation to encourage innovative technology and chest research.
• Cipla has a state of the art Centre for Palliative Care where cancer patients are cared for in their last days, free of charge.
  
  Visit Cipla International Website

Cipla Medpro

• Cipla Medpro was founded 18 years ago by CEO Jerome Smith.
• Today Cipla Medpro is the third largest generic medicines company in South Africa by volume.
• Cipla Medpro is South Africa's third largest pharmaceutical company by value.
• The company is currently growing faster than the top 40 pharmaceutical companies in SA.
• Cipla Medpro is listed on the Johannesburg Securities Exchange (JSE) through holding company Cipla Medpro South Africa Limited
• In December 2005 Cipla Medpro was acquired by local pharmaceutical group Enaleni Ltd for R1,5 billion (one of the largest pharmaceutical transactions ever undertaken in South Africa). Just 18 months later, Jerome Smith was appointed group CEO. In November 2008, the group name was changed to Cipla Medpro South Africa Limited.
• The company was the first in South Africa to launch a three in one ARV combination of a first line regimine (Triomune) in 2006.